Lithium to Prevent or Delay Dementia

What Is This Study About?

This phase 4 clinical trial will test lithium, a drug approved to treat mania, depression, and other mental disorders, as a possible treatment that may delay dementia onset or slow its progression in older adults with mild cognitive impairment (MCI). Participants will be randomly assigned to take either lithium (beginning at 150 mg per day) or a placebo for two years. Participants will receive a neurocognitive assessment, biomarker tests using blood and cerebrospinal fluid samples, and brain imaging, at the start and after each year of the study.

Do I Qualify To Participate in This Study?

Must have:

• Diagnosis of MCI

Must NOT have:

• Major psychiatric illness
• Major neurological illness (e.g., multiple sclerosis)
• Contraindication to lithium (e.g., renal insufficiency)
• Inability to complete neuropsychological testing due to nonremediable impairment such as blindness

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Where Is This Study Located?

Who Sponsors This Study?

Lead: Ariel Gildengers, MD

Collaborator Sponsor

• National Institute on Aging (NIA)

Source: ClinicalTrials.gov ID: NCT03185208